Abstract 2475: MB5029: A novel anti-PD-1 x IL-2v with improved safety profile and enhanced anti-tumor efficacy by selectively targeting activated T cells
Park, Bom, Bang, Hyojoo, Kim, So Woon, Kim, Suna, Cho, Sunjung, Kim, Suyoon, Kim, Minwoo, Park, Youngjin, Park, Jun-Eui
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 5671: MB201, a CD8+ T cell-selective anti-PD-L1 x IL-2 variant fusion protein, exhibits a potent anti-tumor efficacy without peripheral toxicity
Park, Bom, Bang, Hyojoo, Jung, Youngjun, Cho, Sunjung, Kim, Mi Seong, Kang, Seok Chan, Jung, Sungyoub, Park, Youngjin
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 5677: MB101, a novel PD-L1 x CD3 targeted bispecific antibody, exhibits potent tumor-killing efficacy with minimal off-tumor toxicity
Kim, Suna, Bang, Hyojoo, Jung, Yongjun, Cho, Sunjung, Kim, Youngsam, Park, Sang-hyun, Kang, Seok Chan, Park, Youngjin, Jung, Sungyoub
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article